Zinc Finger Protein 706 Gene a Potential Diagnostic and Therapeutic Target in Hepatocellular Carcinoma: Implications for Cancer Biotechnology.

[BACKGROUND] Zinc finger proteins, particularly Zinc Finger Protein 706 (ZNF706), have been implicated in various cancers, yet their functional and clinical significance in hepatocellular carcinoma (HCC) remains unclear. Identifying novel biomarkers and therapeutic targets is essential for improving HCC diagnosis and treatment.

[OBJECTIVES] To investigate the functional role of ZNF706 in HCC and evaluate its potential as a diagnostic and therapeutic target with biotechnological applications.

[MATERIALS AND METHODS] Bioinformatic analyses were performed using clinical and transcriptomic data from TCGA and GTEx databases to assess ZNF706 expression and its correlation with clinicopathological features and patient prognosis. Quantitative PCR and Western blotting validated ZNF706 expression in liver epithelial and HCC cell lines. Functional assays, including CCK-8, flow cytometry, and Transwell migration/invasion assays, were conducted following ZNF706 knockdown.

[RESULTS] ZNF706 was significantly overexpressed in HCC tissues and cell lines compared to normal controls. High ZNF706 expression correlated with advanced TNM stage, pathological stage, and poor survival outcomes. Knockdown of ZNF706 inhibited proliferation, migration, and invasion, and increased apoptosis in HCC cells. ROC analysis demonstrated high diagnostic accuracy (AUC > 0.90) for ZNF706 in distinguishing HCC and predicting prognosis.

[CONCLUSIONS] ZNF706 is a promising biomarker for HCC diagnosis and prognosis and represents a potential therapeutic target for biotechnological intervention. These findings support the development of ZNF706-based diagnostic assays and targeted therapies for improved management of HCC.